| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14779072.2016.1248406 |
| P698 | PubMed publication ID | 27740860 |
| P2093 | author name string | Benilde Cosmi | |
| P2860 | cites work | Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators | Q43681404 |
| Extended oral anticoagulant therapy after a first episode of pulmonary embolism. | Q44496670 | ||
| High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism | Q45877633 | ||
| Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). | Q47923995 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis | Q50143690 | ||
| D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. | Q50595629 | ||
| Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. | Q51574600 | ||
| Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests. | Q53085685 | ||
| A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
| Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study. | Q53672029 | ||
| D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study | Q56973674 | ||
| Age and gender specific cut-off values to improve the performance of D-dimer assays to predict the risk of venous thromboembolism recurrence | Q56978729 | ||
| Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study | Q56989286 | ||
| Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism | Q57212683 | ||
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 | ||
| Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation | Q28074457 | ||
| Guidance for the evaluation and treatment of hereditary and acquired thrombophilia | Q28077943 | ||
| Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data | Q30889099 | ||
| Aspirin for preventing the recurrence of venous thromboembolism | Q34276812 | ||
| Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term | Q34284224 | ||
| Low-dose aspirin for preventing recurrent venous thromboembolism | Q34309660 | ||
| Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration | Q34435111 | ||
| Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report | Q34513594 | ||
| D-dimer testing to determine the duration of anticoagulation therapy | Q34576728 | ||
| Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited? | Q36201247 | ||
| Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
| Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? | Q37259068 | ||
| Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism | Q37288236 | ||
| D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. | Q37648653 | ||
| D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment | Q38847437 | ||
| Bleeding complications in venous thrombosis patients on well-managed warfarin | Q41056063 | ||
| Screening for Occult Cancer in Unprovoked Venous Thromboembolism | Q41653423 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1371-1384 | |
| P577 | publication date | 2016-10-14 | |
| P1433 | published in | Expert Review of Cardiovascular Therapy | Q15733727 |
| P1476 | title | Management of idiopathic venous thromboembolism | |
| P478 | volume | 14 |
Search more.